Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew D Goodman

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Multiple Sclerosis and Related Disorders|December 16, 2021
Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and ageDejan Jakimovski, Katelyn S Kavak, Caila B Vaughn, et al.
Annals of Neurology|August 26, 2010
Assessment of JC virus DNA in blood and urine from natalizumab-treated patientsRichard A Rudick, Paul W O'Connor, Chris H Polman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 21, 2025
DISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trialJohn R Corboy, Robert J Fox, Gary Cutter, et al.
Neurology|December 3, 2020
Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS StudyRobert T Naismith, Robert A Bermel, Christopher S Coffey, et al.
Annals of Clinical and Translational Neurology|January 18, 2021
Response to ibudilast treatment according to progressive multiple sclerosis disease phenotypeAndrew D Goodman, Janel K Fedler, Jon Yankey, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 30, 2022
Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension studyCorey C Ford, Jeffrey A Cohen, Andrew D Goodman, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 7, 2021
Treating MS after surviving PML: Discrete strategies for rescue, remission, and recovery patient 1: From the National Multiple Sclerosis Society Case Conference ProceedingsNidhiben Anadani, Megan Hyland, Roberto Alejandro Cruz, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 15, 2020
Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosisRobert A Bermel, Janel K Fedler, Peter Kaiser, et al.
BMC Neurology|July 16, 2016
Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC)Robert Zivadinov, Diane L Cookfair, Lauren Krupp, et al.
Journal of Participatory Medicine|July 13, 2021
Correction: Data Sharing Goals for Nonprofit Funders of Clinical TrialsTimothy Coetzee, Mad Price Ball, Marc Boutin, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Multiple Sclerosis and Related Disorders|December 16, 2021
Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and ageDejan Jakimovski, Katelyn S Kavak, Caila B Vaughn, et al.
Annals of Neurology|August 26, 2010
Assessment of JC virus DNA in blood and urine from natalizumab-treated patientsRichard A Rudick, Paul W O'Connor, Chris H Polman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 21, 2025
DISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trialJohn R Corboy, Robert J Fox, Gary Cutter, et al.
Neurology|December 3, 2020
Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS StudyRobert T Naismith, Robert A Bermel, Christopher S Coffey, et al.
Annals of Clinical and Translational Neurology|January 18, 2021
Response to ibudilast treatment according to progressive multiple sclerosis disease phenotypeAndrew D Goodman, Janel K Fedler, Jon Yankey, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 30, 2022
Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension studyCorey C Ford, Jeffrey A Cohen, Andrew D Goodman, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 7, 2021
Treating MS after surviving PML: Discrete strategies for rescue, remission, and recovery patient 1: From the National Multiple Sclerosis Society Case Conference ProceedingsNidhiben Anadani, Megan Hyland, Roberto Alejandro Cruz, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 15, 2020
Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosisRobert A Bermel, Janel K Fedler, Peter Kaiser, et al.
BMC Neurology|July 16, 2016
Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC)Robert Zivadinov, Diane L Cookfair, Lauren Krupp, et al.
Journal of Participatory Medicine|July 13, 2021
Correction: Data Sharing Goals for Nonprofit Funders of Clinical TrialsTimothy Coetzee, Mad Price Ball, Marc Boutin, et al.
Pageof 5